Editas med stock.

Editas Medicine, Inc. Common Stock (EDIT) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Aug 2, 2023 · The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the second quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call. 2.25%. $26.23M. EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA ...What happened. Shares of Editas Medicine (EDIT 3.31%) were up 12.7% this week, as of Thursday's close, according to data provided by S&P Global Market Intelligence.The biotech specializes in gene ...

Stock Quote. Change Volume 52 Week High 52 Week Low Dec 2, 2023 5:42 PM EST. ... Editas Medicine, Inc. Phone: 617.401.0113 E-mail: [email protected] 2, 2023 · The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the second quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call. Editas Medicine ( EDIT 0.86%) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. Over the past year, it has more than doubled investors' money. Meanwhile, the ...

The latest price target for Editas Medicine ( NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023. The analyst firm set a price target for 11.00 …Dec 10, 2020 · This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...

Innovative biochemist with experience leading projects and people. | Learn more about Chrysa Latrick's work experience, education, connections & more by visiting their profile on LinkedInDie Editas Medicine Inc Aktie wird unter der ISIN US28106W1036 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, NASDAQ, London, Moskau, Bats, BX World, NASDAQ Bsc, Gettex ... Discover historical prices for EDIT stock on Yahoo Finance. View daily, weekly or monthly format back to when Editas Medicine, Inc. stock was issued. Nov 3, 2023 · Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.81 per share a year ago.

Shares of Editas Medicine ( EDIT -2.58%) were tumbling 13% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence. The company presented at the ...

The latest price target for Editas Medicine ( NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023. The analyst firm set a price target for 11.00 …

Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This …Editas Medicine stock has received a consensus rating of hold. The average rating score is and is based on 17 buy ratings, 21 hold ratings, and 7 sell ratings. What was the 52-week low for Editas ...Precise correction of the CD40LG gene in T cells and hematopoietic stem/progenitor cells (HSPC) holds promise for treating X-linked hyper-IgM Syndrome (HIGM1), but its actual therapeutic potential remains elusive. Here, we developed a one-size-fits-all editing strategy for effective T-cell correctio …Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis. Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Company Description. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial …11 ago 2021 ... The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise ...Editas Medicine releases earnings for the most recent quarter on November 3. Analysts predict Editas Medicine will release losses per share of $0.575. Go here to track Editas Medicine stock price ...In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.Shares of Editas Medicine ( EDIT 11.39%) were skyrocketing 41.5% higher as of 11:57 a.m. EST on Monday. The company didn't announce any big news over the weekend or today, so why is the …Apr 17, 2023 · Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ... View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

2.25%. $26.23M. EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.Click on the text tab and select a style of your choice. Change the size and color of the selected font to make it fit your design. You can also add some fun elements to make your 2048 x 1152 pixels YouTube channel art-pop. Select the ‘ Objects ’ bar and put in elements that fit the theme of your YouTube banner.Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 19.25% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.27. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.48. Year to date, Editas ...Nov 24, 2023 · Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of its common stock. All of the shares in the offering are to be sold by Editas ...Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ...Get Editas Medicine Inc (EDIT.OQ) real-time stock quotes, news, ... Editas Medicine, Inc. is a clinical-stage genome editing company.See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...

See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. …Investment Thesis. Earlier this year, I wrote an article highlighting Editas Medicine's ( NASDAQ: EDIT) sluggish pace in which it is advancing its drug development programs. Since then, the ...Editas Medicine works with two distinct CRISPR nucleases: Cas9 and Cas12a (also known as Cpf1). Both nucleases have distinct gene editing and targeting capabilities. Using these two nucleases, we can access a …Today's High Today's Low 52 Week High 52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. >> Main navigation. Research and Pipeline; CRISPR …Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...Editas Medicine stock has received a consensus rating of hold. The average rating score is and is based on 17 buy ratings, 21 hold ratings, and 7 sell ratings. What was the 52-week low for Editas ...The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the fourth quarter and full ...Dec 6, 2022 · Editas is a CRISPR/Cas9 gene editing pioneer that's on the right side of a complex patent dispute currently. Its lead candidate EDIT-101 read out disappointing results from a study in eye disease ... View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine. The offering is expected to close on or about January 25, 2021, subject to customary closing conditions.Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 2.25%. $26.23M. EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Conference Call The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the third quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas …View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ.Instagram:https://instagram. schwab bank sweep vs cash balancehalliburton company stockluv airlineschevron in venezuela Shares of Editas Medicine ( EDIT 3.66%) are sliding today, down by 7.2% as of 11:26 a.m. ET. The decline came after the company announced a big shake-up with its research and development focus ... cheapest stocks to buy nownvdy stock The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week low. What was the 52-week high for Editas Medicine ... Let’s look at Editas Medicine (NASDAQ:EDIT).I last mentioned Editas Medicine on Nov. 20, as it traded at around $10. Now up slightly, I expect it to push even higher on two key catalysts. One is ... personal loan for teachers Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ...Editas (EDIT) delivered earnings and revenue surprises of -4.76% and 43.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?